EK
EKTAF.US Elekta AB (publ)
- Market cap
- USD 2.33B
- P/E
- -
- P/B
- 3.05x
- ROE
- 14.0%
- Dividend yield
- 3.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is EKTAF.US undervalued?
Graham numberThe Graham number of Elekta AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elekta AB (publ) fundamental analysis
No fundamental analysis for Elekta AB (publ) yet.
Elekta AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machines and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo, a CT-Linac solution; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-compl…
Full company profileElekta AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elekta AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 10.7B | 11.6B | 13.6B | 14.6B | 13.8B | 14.5B | 16.9B | 18.1B | 18.0B | 16.6B | 14.1B |
| Gross Profit | 3.81B | 4.43B | 4.78B | 4.96B | 4.50B | 4.50B | 5.39B | 6.78B | 6.75B | 6.21B | 6.00B |
| Operating Income | 1.32B | 1.80B | 1.76B | 1.95B | 1.89B | 1.54B | 1.93B | 2.04B | 890M | 431M | 1.55B |
| EBITDA | 1.97B | 2.48B | 2.68B | 2.94B | 3.07B | 2.69B | 2.57B | 3.29B | 2.19B | 1.67B | 2.08B |
| Net Income | 125M | 1.35B | 1.20B | 1.08B | 1.25B | 1.15B | 943M | 1.30B | 237M | -517M | 1.05B |
| EPS | 0.33 | 3.53 | 3.14 | 2.84 | 3.28 | 3.02 | 2.47 | 3.41 | 0.62 | -1.35 | 2.75 |
| Balance Sheet | |||||||||||
| Total Assets | 21.1B | 24.1B | 24.3B | 28.4B | 24.8B | 26.7B | 30.1B | 31.4B | 29.0B | 26.8B | 26.6B |
| Total Liabilities | 14.3B | 17.1B | 16.5B | 20.3B | 16.6B | 17.8B | 20.4B | 20.6B | 20.1B | 19.7B | 19.0B |
| Shareholders' Equity | 6.77B | 6.99B | 7.78B | 8.11B | 8.20B | 8.91B | 9.73B | 10.8B | 8.80B | 7.05B | 7.53B |
| Cash & Short-term Investments | 3.48B | 4.54B | 4.12B | 6.47B | 4.41B | 3.08B | 3.28B | 2.78B | 2.96B | 3.17B | 2.30B |
| Total Debt | 5.27B | 5.34B | 4.56B | 9.36B | 6.24B | 5.70B | 6.67B | 7.25B | 7.57B | 7.33B | 6.80B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.82B | 2.40B | 1.62B | 1.01B | 2.55B | 1.86B | 1.96B | 2.46B | 2.63B | 2.45B | 0.00 |
| Capital Expenditure | 774M | 854M | 659M | 762M | 845M | 1.41B | 1.56B | 1.64B | 1.57B | 119M | 95.6M |
| Free Cash Flow | 1.05B | 1.55B | 962M | 252M | 1.71B | 450M | 400M | 817M | 1.06B | 2.33B | -95.6M |
| Ratios | |||||||||||
| ROE | 1.8% | 19.3% | 15.4% | 13.4% | 15.3% | 12.9% | 9.7% | 12.1% | 2.7% | -7.3% | 14.0% |
| ROA | 0.6% | 5.6% | 4.9% | 3.8% | 5.0% | 4.3% | 3.1% | 4.1% | 0.8% | -1.9% | 4.0% |
| Net Profit Margin | 1.2% | 11.6% | 8.8% | 7.4% | 9.1% | 7.9% | 5.6% | 7.2% | 1.3% | -3.1% | 7.5% |
| Debt to Equity | 0.78x | 0.76x | 0.59x | 1.15x | 0.76x | 0.64x | 0.69x | 0.67x | 0.86x | 1.04x | 0.90x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Elekta AB (publ) dividends
- Dividend yield
- 3.94%
- Forward dividend
- 0.24 USD
- Payout ratio
- -
- Ex-dividend date
- Mar 4, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | SEK 911M | 2.37 | - |
| 2025 | SEK 917M | 2.40 | 386.9% |
| 2024 | SEK 917M | 2.40 | 70.4% |
| 2023 | SEK 917M | 2.40 | 97.2% |
| 2022 | SEK 841M | 2.20 | 72.9% |
| 2021 | SEK 688M | 1.80 | 54.9% |
| 2020 | SEK 688M | 1.80 | 63.5% |
| 2019 | SEK 535M | 1.40 | 44.7% |
| 2018 | SEK 382M | 1.00 | 28.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Sep 12, 2012.
Who owns Elekta AB (publ)
- Insiders 2.23%
- Institutions 69.84%
- Public & others 27.93%
- Shares outstanding 367M
- Free float 326M
Elekta AB (publ) company profile
- Company name
- Elekta AB (publ)
- Ticker
- EKTAF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,996
- Fiscal year end
- April
- Address
- Hagaplan 4, Stockholm, Sweden, 113 68
- Phone
- 46 8 58 72 54 00
- Website
- elekta.com
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machines and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo, a CT-Linac solution; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Elekta Care, a personalized services for radiotherapy suites. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Elekta Geneva, an applicator for cervical cancer patients; and Elekta Xoft Axxent electronic brachytherapy systems. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning; Elekta Care Community, a self-help center; and Elekta Partner Community, an online self-service portal. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Elekta AB (publ) management
10- Dr. Laurent LeksellFounder & Chairman · born 1952
- Mr. Jakob Just-BomholtCEO & President · born 1974
- Ms. Klara EiritzChief Financial Officer · born 1979
- Rodolfo VelascoChief Operating Officer
- Mr. Christopher BuschChief Product & Technology Officer · born 1969
- Mr. Peter NyquistHead of Investor Relations · born 1965
- Kathy PajariHead of Corporate Communications
- Ms. Christina RaaschouChief Human Resources Officer · born 1977
- Mr. John LapréChief Business Line Officer · born 1964
- Ms. Caroline Leksell CookeSenior VP & Head of Neuro Solutions · born 1981